LLY Eli Lilly and Company | $787.00
+1.2% | +1.7%
 | Kisunla
For the Treatment of Early Symptomatic Alzheimer's Disease | | 7/9/2025 - FDA approved
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved a la…
Full Summary |
EXAS Exact Sciences | $55.31
+3.3% | +1.2%
 | Oncodetect™
Molecular Residual Disease Test | | 7/9/2025 - Provided Update
Exact Sciences Corp announced that its Oncodetect™ molecular residual disease (MRD) test has recei…
Full Summary |
KRYS Krystal Biotech | $148.90
+3.9% | +9.4%
 | KB801
For the Treatment of Neurotrophic Keratitis | Phase 1/2 | 7/9/2025 - Dose Update
Krystal Biotech, Inc announced that the first patient has been dosed in its Phase 1/2 clinical trial…
Full Summary |
RZLT Rezolute | $5.28
+6.2% | +22.5%
 | Ersodetug
For Hypoglycemia Due to Congenital Hyperinsulinism |
Phase 3 | 7/9/2025 - Abstract
Rezolute, Inc announced that the abstract titled "Preliminary Patient Demographics And Baseline Char…
Full Summary |
BCTX Briacell Therap | $2.11
-27.5% | -39.4%
 | Bria-OTS
In metastatic breast cancer | | 7/9/2025 - Provided Update
BriaCell Therapeutics Corp announced the sustained complete resolution of lung metastasis in a patie…
Full Summary |
ALT Altimmune | $4.74
+3.5% | -20.3%
 | pemvidutide
for the treatment of obesity and MASH |
Phase 2 | 7/9/2025 - Enrollment Update
Altimmune, Inc. announced that it has enrolled the first patient in the RESTORE Phase 2 trial evalua…
Full Summary |
BIVI BioVie | $8.05
-5.0% | -28.1%
 | Bezisterim
For Parkinson's Disease Patients | | 7/9/2025 - Provided Update
BioVie Inc. presented "Bezisterim Epigenetic Effects on Aging and Neurodegeneration" at the 7th Worl…
Full Summary |
EOLS Evolus | $9.66
+4.3% | +0.1%
 | Nuceiva®
For the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients2. | | 7/9/2025 - Provided Update
Evolus, Inc announced it has partnered with Symatese to commence distribution of Nuceiva® (botulinu…
Full Summary |
BHC Bausch Health Cos | $6.59
-1.6% | +35.0%
 | CABTREO
For the Treatment of Acne Vulgaris | | 7/9/2025 - Provided Update
Bausch Health, Canada Inc announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl …
Full Summary |
KALA KALA BIO | $6.30
+22.1% | +53.3%
 | KPI-012
Clinical diagnosis of PCED | | 7/9/2025 - Enrollment Completion
KALA BIO, Inc. announced the completion of patient enrollment in the CHASE (Corneal Healing After SE…
Full Summary |
KALA KALA BIO | $6.30
+22.1% | +53.3%
| KPI-012
Clinical diagnosis of PCED | Target date: 2025-Q3 | 7/9/2025 - Top-line results
KALA BIO, Inc. announced that Topline results from the CHASE trial expected by end of Q3 2025 --
Full Summary |
RYTM Rhythm Pharmaceuticals | $89.00
+36.6% | +33.4%
 | bivamelagon
In patients with acquired hypothalamic obesity. |
Phase 2 | 7/9/2025 - Top-line results
Rhythm Pharmaceuticals, Inc. announced positive topline results from its Phase 2 trial evaluating bi…
Full Summary |
BHC Bausch Health Cos | $6.59
-1.6% | +35.0%
| PrCABTREOTM
For Treatment Of Acne Vulgaris | | 7/9/2025 - Provided Update
Bausch Health, Canada Inc., part of Bausch Health Companies Inc. announced that PrCABTREOTM (clinda…
Full Summary |
BNTC Benitec Biopharma | $13.84
+9.7% | -14.4%
 | BB-301
Oculopharyngeal Muscular Dystrophy (OPMD) | Phase 1b/2a | 7/9/2025 - Enrollment Update
Benitec Biopharma Inc. announced the recommendation of the independent Data Safety Monitoring Board…
Full Summary |
ELAN Elanco Animal Health | $14.80
+0.3% | +6.2%
 | TruCan™ Ultra
Canine Influenza Vaccine | | 7/9/2025 - Approved
Elanco Animal Health announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra …
Full Summary |
ASBP Aspire Biopharma | $0.33
+4.1% | -17.5%
 | BUZZ BOMB
New Sublingual Pre-Workout Supplement | | 7/9/2025 - Positive Feedback
Aspire Biopharma Holdings, Inc. announced positive initial consumer feedback from the Company's samp…
Full Summary |
MTVA MetaVia | $0.69
+8.2% | -3.9%
 | DA-1726
For The Treatment Of Obesity |
Phase 1 | 7/9/2025 - Dosing Update
MetaVia Inc. announced dosing of the first patient in the 48 mg, multiple ascending dose (MAD) coho…
Full Summary |
MTVA MetaVia | $0.69
+8.2% | -3.9%
| DA-1726
For The Treatment Of Obesity | Target date: 2025-Q4 | 7/9/2025 - Top-line data
MetaVia Inc. announced that Top-Line Data Expected in the Fourth Quarter of 2025
Full Summary |
CNTB Connect Biopharma | $1.09
-4.1% | +39.4%
 | Rademikibart
For Moderate-To-Severe Atopic Dermatitis |
NDA | 7/9/2025 - NDA Filing
Connect Biopharma Holdings Limited announced that the Company's collaborator and exclusive licensee…
Full Summary |
MRK Merck & Co., Inc. | $83.74
+2.9% | +5.6%
 | MK-8527
novel nucleoside reverse transcriptase translocation inhibitor | | 7/8/2025 - New Data
Merck announced that new data from its research pipeline for HIV prevention and treatment will be p…
Full Summary |
ETON Eton Pharmaceuticals | $15.77
-0.2% | -0.5%
 | ET-600
For the treatment of an endocrinology |
NDA | 7/8/2025 - FDA review
Eton Pharmaceuticals, Inc announced the Company's New Drug Application (NDA) for ET-600, a propriet…
Full Summary |
ETON Eton Pharmaceuticals | $15.77
-0.2% | -0.5%
| ET-600
For the treatment of an endocrinology |
NDA
Target date: 2026-02-25 | 7/8/2025 - PDUFA Date
Eton Pharmaceuticals, Inc announced that NDA has been assigned a Prescription Drug User Fee Act (…
Full Summary |
LRMR Larimar Therapeutics | $3.46
+4.2% | +30.1%
 | nomlabofusp
For Friedreich's Ataxia | | 7/8/2025 - Publication
Larimar Therapeutics, announced the publication of two peer-reviewed articles highlighting nonclin…
Full Summary |
EPRX Eupraxia Pharmaceuticals | $5.46
-2.3% | +37.5%
 | EP-104GI
For Treatment of Eosinophilic Esophagitis |
Phase 2b | 7/8/2025 - Dose Update
Eupraxia Pharmaceuticals Inc. announced the first patient dosed in the Phase 2b randomized, placebo-…
Full Summary |
UPB Upstream Bio | $11.70
+7.3% | +3.6%
 | Verekitug
In Chronic Obstructive Pulmonary Disease (COPD) |
Phase 2 | 7/8/2025 - Dose Update
Upstream Bio, Inc. announced that the first patient has been dosed in the Company's Phase 2 clinica…
Full Summary |
PSTV Plus Therapeutics | $0.35
+5.9% | +1.3%
 | REYOBIQ™
For Patients with Leptomeningeal Metastases | | 7/8/2025 - Provided Update
Plus Therapeutics, Inc. announced the treatment of its initial patients in the Company's ReSPECT-LM…
Full Summary |
ARWR Arrowhead Pharmaceuticals | $18.88
+7.6% | +13.9%
 | Zodasiran
For the Treatment of Homozygous Familial Hypercholesterolemia |
Phase 3 | 7/8/2025 - Dose Update
Arrowhead Pharmaceuticals, Inc. announced that it has dosed the first subject in the YOSEMITE Phase …
Full Summary |
BCLI Brainstorm Cell Therapeutics | $1.24
-5.3% | | NurOwn
Progressive Multiple Sclerosis (MS) | | 7/8/2025 - Provided Update
BrainStorm Cell Therapeutics Inc today acknowledged that the U.S. Food and Drug Administration's (F…
Full Summary |
ITCI Intra-Cellular Therapies | $131.87
| | CAPLYTA (Lumateperone)
Depressive Episodes associated with Bipolar | supplemental New Drug Application (sNDA) | 7/8/2025 - sNDA Filing
Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S.…
Full Summary |
JNJ Johnson & Johnson | $156.07
+0.2% | +0.6%
 | CAPLYTA (Lumateperone)
Depressive Episodes associated with Bipolar | supplemental New Drug Application (sNDA) | 7/8/2025 - sNDA Filing
Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S.…
Full Summary |
ONCY Oncolytics Biotech | $1.20
-4.0% | +169.8%
 | Pelareorep
In Breast Cancer | | 7/8/2025 - Clinical Data
Oncolytics Biotech® Inc announced a strategic update highlighting its compelling clinical data from…
Full Summary |
MAT Mattel | $20.14
+0.2% | +5.7%
 | Barbie
type 1 diabetes (T1D) | | 7/8/2025 - Provided Update
Mattel, Inc announced that Barbie® is debuting the first Barbie doll with type 1 diabetes (T1D).
Full Summary |
RYTM Rhythm Pharmaceuticals | $89.00
+36.6% | +33.4%
| bivamelagon
In patients with acquired hypothalamic obesity. |
Phase 2 | 7/8/2025 - Provided Update
Rhythm Pharmaceuticals, Inc announced the Company will hold a conference call and webcast on Wednes…
Full Summary |
SLDB Solid Biosciences | $5.52
+5.3% | +19.5%
 | SGT-501
For the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) |
IND | 7/8/2025 - FDA Approval
Solid Biosciences Inc. announced approval of its Investigational New Drug (IND) application by the …
Full Summary |
SLDB Solid Biosciences | $5.52
+5.3% | +19.5%
| SGT-501
For the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) |
Phase 1b | 7/8/2025 - Clinical Trial
Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 -
Full Summary |
KALV KalVista Pharmaceuticals | $15.99
+7.0% | +8.3%
 | sebetralstat
Therapy for hereditary angioedema (HAE). | | 7/7/2025 - FDA Approval
KalVista Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has approv…
Full Summary |
TNXP Tonix Pharmaceuticals | $38.36
+7.9% | -2.1%
 | TNX-801
Potential Vaccine to Prevent Mpox and Smallpox | | 7/7/2025 - Data Presentation
Tonix Pharmaceuticals announced that Sina Bavari, PhD, Executive Vice President of Infectious Diseas…
Full Summary |
NTRA Natera | $161.75
+2.1% | -1.5%
 | Latitude™
For Colorectal Cancer | | 7/7/2025 - Data
Natera, Inc announced data from a colorectal cancer (CRC) study of its tissue-free Latitude™ MRD as…
Full Summary |
BSX Boston Scientific | $102.96
+0.5% | +2.9%
 | FARAPULSE™
A nonthermal treatment in which electric fields selectively ablate heart tissue in patients with atrial fibrillation (AF). | | 7/7/2025 - FDA Approval
Boston Scientific Corporation announced that it has received U.S. Food and Drug Administration (FDA…
Full Summary |
BYSI BeyondSpring | $2.31
+4.5% | +4.5%
 | plinabulin
Patients with non-small cell lung cancer | | 7/7/2025 - Publication
BeyondSpring Inc. announced publication of a human clinical study in Med (Cell Press) demonstrating…
Full Summary |
COGT Cogent Biosciences | $10.40
+6.3% | +50.7%
 | bezuclastinib
In patients with non-advanced systemic mastocytosis | | 7/7/2025 - Top-line results
Cogent Biosciences, Inc. announced positive top-line results from the registration-directed Part 2 …
Full Summary |
OGN Organon & Co. | $9.96
+0.1% | +2.0%
 | VTAMA (tapinarof) cream
Plaque psoriasis | | 7/7/2025 - Recommendation
Organon announced that VTAMA® (tapinarof) cream, 1%,was granted a strong recommendation by the Ameri…
Full Summary |
JSPR Jasper Therapeutics | $3.68
+21.9% | -38.0%
 | Briquilimab
To address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) | Phase 1b/2a | 7/7/2025 - Updated data
Jasper Therapeutics is reporting updated data from Company's BEACON Phase 1b/2a study of subcutaneo…
Full Summary |
URGN Urogen Pharma | $13.81
+0.7% | +96.7%
 | UGN-103
For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer |
Phase 3 | 7/7/2025 - Enrollment Completion
UroGen Pharma Ltd. announced that it has completed patient enrollment in its Phase 3 UTOPIA clinica…
Full Summary |
DNLI Denali Therapeutics | $15.00
+4.7% | +2.4%
 | tividenofusp
For the treatment of Hunter syndrome (MPS II) | BLA | 7/7/2025 - FDA review
Denali Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for…
Full Summary |
DNLI Denali Therapeutics | $15.00
+4.7% | +2.4%
| tividenofusp
For the treatment of Hunter syndrome (MPS II) | BLA
Target date: 2026-01-05 | 7/7/2025 - PDUFA Date
Denali Therapeutics Inc. announced that The FDA granted the BLA Priority Review with a Prescription…
Full Summary |
KALA KALA BIO | $6.30
+22.1% | +53.3%
| KPI-012
Clinical diagnosis of PCED | | 7/7/2025 - Provided Update
KALA BIO, Inc. announced that the Company will host a webcast event with Key Opinion Leaders (KOLs…
Full Summary |
AGEN Agenus | $5.18
+6.6% | -6.7%
 | BOT/BAL
In Metastatic MSS Colorectal Cancer |
Phase 3 | 7/7/2025 - Provided Update
Agenus also confirmed that it has reached agreement with the U.S. Food and Drug Administration (FDA)…
Full Summary |
FBIO Fortress Biotech | $1.99
+3.1% | -6.6%
 | MB-101
Leptomeningeal brain tumors | Orphan Drug | 7/7/2025 - Designation Grant
Mustang Bio, Inc announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Dr…
Full Summary |
MBIO Mustang Bio | $3.11
+16.9% | +141.1%
 | MB-101
Leptomeningeal brain tumors | Orphan Drug | 7/7/2025 - Designation Grant
Mustang Bio, Inc announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Dr…
Full Summary |
IINN Inspira Technologies OXY B.H.N. | $1.44
-3.4% | +97.3%
 | ART100
Cardio-Pulmonary Bypass Device | | 7/7/2025 - Provided Update
Inspira™ Technologies OXY B.H.N. Ltd. announced that it is engaged in high-level talks with a gover…
Full Summary |
IMMX Immix Biopharma | $2.75
+3.4% | +17.5%
 | NXC-201
NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. | | 7/7/2025 - Provided Update
Immix Biopharma, Inc. announced accelerated U.S. NEXICART-2 clinical trial progress in relapsed/ref…
Full Summary |
ASND Ascendis Pharma A/S | $175.71
+4.5% | +1.5%
 | TransCon PTH
Adult Hypoparathyroidism | | 7/7/2025 - Oral presentation
Ascendis Pharma A/S announced two oral presentations at ENDO 2025, the annual meeting of the Endoc…
Full Summary |
APGE Apogee Therapeutics | $37.02
+1.7% | -7.7%
 | APG777
For the Treatment for Atopic Dermatitis and Other Inflammatory Diseases |
Phase 2 | 7/6/2025 - Data
Apogee Therapeutics, Inc announced it will report Part A 16-week data from the Phase 2 APEX trial o…
Full Summary |
NVS Novartis | $122.95
+1.0% | +4.2%
 | secukinumab
In adults with newly diagnosed or relapsing giant cell arteritis (GCA). |
Phase 3 | 7/3/2025 - Top-line results
Novartis announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinu…
Full Summary |
BCAB BioAtla | $0.39
-0.1% | -23.6%
 | BA3182
In Patients with Treatment Refractory Metastatic Adenocarcinoma | | 7/3/2025 - Data Presentation
BioAtla, Inc today presented first-in-human data in a poster titled "Preliminary Results from a Fir…
Full Summary |
MIRA MIRA Pharmaceuticals | $1.13
| -12.4%
 | MIRA-55
Potential treatment for anxiety and cognitive decline. | | 7/3/2025 - Preclinical Data
MIRA Pharmaceuticals, Inc. announced positive preclinical data demonstrating that Mira-55, the Com…
Full Summary |
VRTX Vertex Pharmaceuticals | $478.96
+2.7% | +7.4%
 | exagamglogene autotemcel
For severe sickle cell disease | | 7/3/2025 - Positive Data
Vertex Pharmaceuticals announced positive longer-term data for PrCASGEVY® (exagamglogene autotemcel…
Full Summary |
BLTE Belite Bio | $64.16
+6.7% | +4.5%
 | Tinlarebant
In Stargardt Disease |
Phase 3 | 7/2/2025 - Enrollment Update
Belite Bio, Inc announced the completion of enrollment in the PHOENIX trial, a global, 24-month Phas…
Full Summary |
TIL Instil Bio | $25.63
+9.4% | -26.9%
 | AXN-2510
In Relapsed/Refractory Solid Tumors |
IND | 7/2/2025 - FDA Clearance
Instil Bio, Inc. announced the clearance of an Investigational New Drug (IND) application for AXN-25…
Full Summary |
MRK Merck & Co., Inc. | $83.74
+2.9% | +5.6%
| sotatercept-csrk
In adults with pulmonary arterial hypertension | BLA Priority Review | 7/2/2025 - FDA GRANT
Merck announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority r…
Full Summary |
MRK Merck & Co., Inc. | $83.74
+2.9% | +5.6%
| sotatercept-csrk
In adults with pulmonary arterial hypertension | BLA Priority Review
Target date: 2025-10-25 | 7/2/2025 - PDUFA Date
Merck announced that The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action date…
Full Summary |
CTSO Cytosorbents | $1.11
+5.7% | +2.8%
 | DrugSorb-ATR
Antithrombotic Removal System | | 7/2/2025 - Regulatory Update
CytoSorbents Corporation today provided a regulatory update on its marketing applications for DrugS…
Full Summary |
TNXP Tonix Pharmaceuticals | $38.36
+7.9% | -2.1%
| TNX-1700
Recombinant human TFF2-human serum albumin or HSA) for the treatment of colon and gastric cancers. | | 7/2/2025 - Publication
Tonix Pharmaceuticals Holding Corp announced the publication of a paper entitled, "A CXCR4 Partial…
Full Summary |
OGN Organon & Co. | $9.96
+0.1% | +2.0%
| OG-6219
In Patients with Endometriosis-Related Pain |
Phase 2 | 7/2/2025 - Endpoint Missed
Organon announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational cand…
Full Summary |
VYNE VYNE Therapeutics | $1.44
+4.3% | +50.2%
 | VYN202
A Novel BD2-Selective BET Inhibitor |
Phase 1b | 7/2/2025 - Provided Update
VYNE Therapeutics Inc today provided a program update for VYN202 following the clinical hold issue…
Full Summary |
CERS Cerus | $1.49
+2.1% | +1.4%
 | INTERCEPT Blood System
for platelets, plasma, IFC, and red blood cells | | 7/2/2025 - Regulatory Update
Cerus Corporation announced a European regulatory update on the INTERCEPT RBC program.
Full Summary |
IINN Inspira Technologies OXY B.H.N. | $1.44
-3.4% | +97.3%
| ART100
Cardio-Pulmonary Bypass Device | | 7/2/2025 - Provided Update
Inspira™ Technologies OXY B.H.N. Ltd. announced it has secured a binding $22.5 million purchase or…
Full Summary |
REGN Regeneron Pharmaceuticals | $552.58
+0.9% | +6.8%
 | linvoseltamab-gcpt
For Treatment of Relapsed or Refractory Multiple Myeloma | | 7/2/2025 - FDA GRANT
Regeneron Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has grant…
Full Summary |
IMAB I-Mab | $2.31
+5.0% | -17.5%
 | Givastomig
In patients with advanced cancers |
Phase 1b | 7/2/2025 - Positive Data
I-Mab announced the presentation of positive Phase 1b combination data for givastomig, in combinati…
Full Summary |
IVA Inventiva | $3.37
-2.6% | -7.0%
 | Lanifibranor
Nonalcoholic steatohepatitis (NASH) |
Phase 2b | 7/2/2025 - Publication
Inventiva announces the publication in Journal of Hepatology Reports, a peer-reviewed, scientific jo…
Full Summary |
FDMT 4D Molecular Therapeutics | $4.42
+4.7% | -7.7%
 | 4D-150
Intravitreal vector, R100, and a transgene payload that expresses both aflibercept and a VEGF-C inhibitory RNAi. |
Phase 3 | 7/2/2025 - Provided Update
4D Molecular Therapeutics announced the acceleration of the 4D-150 4FRONT Phase 3 program in wet ag…
Full Summary |
ATAI atai Life Sciences | $2.66
+1.1% | +16.7%
 | BPL-003
In Patients With Treatment Resistant Depression |
Phase 2b | 7/1/2025 - Top-line results
atai Life Sciences and Beckley Psytech Limited jointly announced positive topline results from the…
Full Summary |
NVCR NovoCure | $18.19
+3.9% | +7.6%
 | Tumor Treating Fields - PANOVA-3
Locally advanced pancreatic cancer |
Phase 3 | 7/1/2025 - Results
Novocure announced that it will present the final secondary endpoint results from the Phase 3 PANOV…
Full Summary |
BTAI BioXcel Therapeutics | $2.00
-0.5% | +2.0%
 | BXCL501 (SERENITY)
Schizophrenia and bipolar disorders | | 7/1/2025 - Recommendation
BioXcel Therapeutics announced the second positive recommendation by an independent Data Safety Moni…
Full Summary |
BTAI BioXcel Therapeutics | $2.00
-0.5% | +2.0%
| BXCL501 (SERENITY)
Schizophrenia and bipolar disorders | Target date: 2025-Q3 | 7/1/2025 - Top-line data
BioXcel Therapeutics, Inc announced that Topline data expected in Q3 2025.
Full Summary |
ADPT Adaptive Biotechnologies | $11.93
+1.6% | +14.2%
 | clonoSEQ
Treatments for patients with lymphoid malignancies. | | 7/1/2025 - Provided Update
Adaptive Biotechnologies announced the integration of Adaptive's clonoSEQ® test for measurable resi…
Full Summary |
SLNO Soleno Therapeutics | $88.49
+3.8% | +13.8%
 | VYKAT XR
To Treat Hyperphagia in Prader-Willi Syndrome | | 7/1/2025 - Abstract Presentation
Soleno Therapeutics, announced that two abstracts featuring data on VYKAT™ XR (diazoxide choline) ex…
Full Summary |
JAZZ Jazz Pharmaceuticals | $111.60
+2.3% | -0.2%
 | Ziihera
For the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) | European Commission Conditional Marketing Authorization | 7/1/2025 - Marketing authorization
Jazz Pharmaceuticals plc announced that the European Commission (EC) has granted conditional market…
Full Summary |
FBIO Fortress Biotech | $1.99
+3.1% | -6.6%
| MB-101
Leptomeningeal brain tumors | Orphan Drug | 7/1/2025 - Designation Grant
Mustang Bio Receives FDA Orphan Drug Designation For MB-101 Treatment Of Malignant Glioma
Full Summary |
MBIO Mustang Bio | $3.11
+16.9% | +141.1%
| MB-101
Leptomeningeal brain tumors | Orphan Drug | 7/1/2025 - Designation Grant
Mustang Bio Receives FDA Orphan Drug Designation For MB-101 Treatment Of Malignant Glioma
Full Summary |
BTAI BioXcel Therapeutics | $2.00
-0.5% | +2.0%
| BXCL501 (SERENITY)
Schizophrenia and bipolar disorders | | 7/1/2025 - Recommendation
BioXcel Therapeutics, Inc. announced the second positive recommendation by an independent Data Safe…
Full Summary |
CUE Cue Biopharma | $0.78
+6.9% | +23.0%
 | CUE-101
HPV+ recurrent/metastatic head and neck cancer | | 7/1/2025 - Provided Update
Cue Biopharma, provided an update on its most advanced clinical stage asset, CUE-101, representative…
Full Summary |
ARGX argenex | $555.19
+3.1% | -4.9%
 | ARGX-119
In Congenital Myasthenic Syndromes |
Phase 1b | 6/30/2025 - Provided Update
argenx SE announced its plan to advance the clinical development of ARGX-119, a first-in-class agon…
Full Summary |
AZN AstraZeneca | $70.82
+1.1% | -3.0%
 | TAGRISSO® (osimertinib)
Third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. |
NDA | 6/30/2025 - Approved
HUTCHMED (China) Limited announces that the New Drug Application ("NDA") for the combination of ORP…
Full Summary |
RCKT Rocket Pharmaceuticals | $3.20
+8.1% | +6.0%
 | RP-A701
For the Treatment of BAG3-associated Dilated Cardiomyopathy |
IND | 6/30/2025 - FDA Clearance
Rocket Pharmaceuticals, Inc. announced that it has received clearance from the U.S. Food and Drug Ad…
Full Summary |
SAVA Cassava Sciences | $2.19
+5.3% | +1.9%
 | Simufilam
Alzheimer's Disease | | 6/30/2025 - Poster Presentation
Cassava Sciences, Inc. announced that the Company presented a poster at the TSC International Resea…
Full Summary |
AVDL Avadel Pharmaceuticals | $9.55
+5.6% | -5.2%
 | LUMRYZ (sodium oxybate)
Extended-release sodium oxybate medication | | 6/30/2025 - Regulatory Update
Avadel Pharmaceuticals plc announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for t…
Full Summary |
MRNA Moderna | $32.79
+0.8% | +16.5%
 | mRNA-1010
Quadrivalent Seasonal Flu |
Phase 3 | 6/30/2025 - Positive Results
Moderna, Inc. announced positive results from a Phase 3 efficacy study (P304) evaluating the relativ…
Full Summary |
CELC Celcuity | $13.51
+0.8% | +4.6%
 | Gedatolisib
HR+ / HER2- Metastatic Breast Cancer | | 6/30/2025 - Clinical Data
Celcuity Inc. announced preliminary clinical data for gedatolisib in two early phase clinical trials…
Full Summary |
PSTV Plus Therapeutics | $0.35
+5.9% | +1.3%
| REYOBIQ™
For Patients with Leptomeningeal Metastases | | 6/30/2025 - Trial Initiation
Plus Therapeutics, Inc announces the initiation of the ReSPECT-LM dose optimization trial for REYOBI…
Full Summary |
INMB INmune Bio | $2.36
+2.6% | -69.2%
 | XPro
For treatment of Alzheimer's Disease | | 6/30/2025 - Findings Update
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease
Full Summary |
BIIB Biogen | $133.02
-1.1% | -0.8%
 | Felzartamab
For the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients | | 6/30/2025 - Dosing Update
Biogen Inc. announced the initiation of dosing in the global clinical study, PROMINENT.
Full Summary |
ASMB Assembly Biosciences | $18.72
+3.5% | +16.5%
 | ABI-1179
For Recurrent Genital Herpes |
Phase 1 | 6/30/2025 - Dosing Update
Assembly Biosciences, Inc. announced that the first participant has been dosed in the Phase 1b porti…
Full Summary |
CMMB Chemomab Therapeutics | $1.17
+0.9% | -11.4%
 | nebokitug
In Sclerosing Cholangitis |
Phase 2 | 6/30/2025 - Data Presentation
Chemomab Therapeutics, Ltd announced that data from the company's Phase 2 SPRING trial of nebokitug…
Full Summary |
TPST Tempest Therapeutics | $7.52
+1.1% | -16.0%
 | TPST-1120
First-Line Regimen for Hepatocellular Carcinoma | | 6/30/2025 - Received Approval
Tempest Therapeutics, Inc. announced that the company received approval from the National Medical P…
Full Summary |
CRBP Corbus Pharmaceuticals | $8.37
+11.0% | -9.1%
 | CRB-913
For Obesity |
Phase 1 | 6/30/2025 - Dose Update
Corbus Pharmaceuticals Holdings Inc. announced the initiation of the multiple ascending dose (MAD) p…
Full Summary |
MESO Mesoblast | $10.51
+0.6% | -11.3%
 | Revascor
In the treatment of the congenital heart disease hypoplastic left heart syndrome (HLHS). | BLA | 6/30/2025 - Provided Update
Mesoblast announced alignment with the United States Food and Drug Administration (FDA) on items req…
Full Summary |
AUPH Aurinia Pharmaceuticals | $8.39
+10.5% | +3.1%
 | AUR 200
For B-cell mediated autoimmune diseases. | | 6/29/2025 - Provided Update
Aurinia Pharmaceuticals Inc announced that it will host a webcast and conference call on June 30, 2…
Full Summary |
PHVS Pharvaris | $18.50
+2.9% | +2.6%
 | Deucrictibant
For bradykinin-B2-receptor | | 6/27/2025 - Abstract Presentation
Pharvaris announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Ass…
Full Summary |
